Postherpetic Neuralgia

Also known as: Neuralgia,Postherpetic / Neuralgia, Postherpetic / Post-herpetic neuralgia / Post herpetic neuralgia / PHN

DrugDrug NameDrug Description
DB00575ClonidineClonidine, an imidazoline-derivative hypotensive agent is a centrally-acting α2-adrenergic agonist. It crosses the blood-brain barrier and acts in the hypothalamus to induce a decrease in blood pressure. It may also be administered as an epidural infusion as an adjunct treatment in the management of severe cancer pain that is not relieved by opiate analgesics alone. Clonidine may be used for differential diagnosis of pheochromocytoma in hypertensive patients. Other uses for clonidine include prophylaxis of vascular migraine headaches, treatment of severe dysmenorrhea, management of vasomotor symptoms associated with menopause, rapid detoxification in the management of opiate withdrawal, treatment of alcohol withdrawal used in conjunction with benzodiazepines, management of nicotine dependence, topical use to reduce intraocular pressure in the treatment of open-angle and secondary glaucoma and hemorrhagic glaucoma associated with hypertension, and in the treatment of attention-deficit hyperactivity disorder (ADHD). Clonidine also exhibits some peripheral activity.
DB01151DesipramineDesipramine hydrochloride is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, desipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, desipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Secondary amine TCAs, such as desipramine and nortriptyline, are more potent inhibitors of norepinephrine reuptake than tertiary amine TCAs, such as amitriptyline and doxepine. TCAs also down-regulate cerebral cortical β-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine-H1 receptors, α1-adrenergic receptors and muscarinic receptors, which accounts for their sedative, hypotensive and anticholinergic effects (e.g. blurred vision, dry mouth, constipation, urinary retention), respectively. See toxicity section below for a complete listing of side effects. Desipramine exerts less anticholinergic and sedative side effects compared to tertiary amine TCAs, such as amitriptyline and clomipramine. Desipramine may be used to treat depression, neuropathic pain (unlabeled use), agitation and insomnia (unlabeled use) and attention-deficit hyperactivity disorder (unlabeled use).
DB00281LidocaineEver since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication [T583]. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L5930, L5948, F4468]. Nevertheless, lidocaine's local anesthetic action sees its use in many medical situations or circumstances that may benefit from its action, including the treatment of premature ejaculation [A177625]. Regardless, lidocaine is currently available as a relatively non-expensive generic medication that is written for in millions of prescriptions internationally on a yearly basis. It is even included in the World Health Organization's List of Essential Medicines [L6055].
DB09543Methyl salicylateMethyl salicylate (oil of wintergreen or wintergreen oil) is an organic ester naturally produced by many species of plants, particularly wintergreens. The compound was first extracted and isolated from plant species Gaultheria procumbens in 1843. It can be manufactured synthetically and it used as a fragrance, in foods, beverages, and liniments. It forms a colorless to yellow or reddish liquid and exhibits a characteristic odor and taste of wintergreen. For acute joint and muscular pain, methyl salicylate is used as a rubefacient and analgesic in deep heating liniments. It is used as a flavoring agent in chewing gums and mints in small concentrations and added as antiseptic in mouthwash solutions.
DB00230PregabalinPregabalin is an anticonvulsant drug used for neuropathic pain, epilepsy and generalized anxiety disorder.[A31161] Although as per the FDA Label the mechanism of action has not been definitively defined, there is evidence that pregabalin achieves antihyperalgesic activity by binding to the α2δ subunit of the voltage-dependent calcium channels [A31162]. Pregabalin is marketed by Pfizer under the trade name Lyrica and Lyrica Cr (extended release).[L1006][FDA Label] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders [A31161].
DrugDrug NameTargetType
DB00575ClonidineAlpha-2A adrenergic receptortarget
DB00575ClonidineCytochrome P450 2D6enzyme
DB00575ClonidineAlpha-2B adrenergic receptortarget
DB00575ClonidineAlpha-2C adrenergic receptortarget
DB00575ClonidineSolute carrier family 22 member 3transporter
DB00575ClonidineSolute carrier family 22 member 5transporter
DB00575ClonidineSolute carrier family 22 member 4transporter
DB00575ClonidineMultidrug resistance protein 1transporter
DB00575ClonidineCytochrome P450 1A2enzyme
DB00575ClonidineCytochrome P450 3A4enzyme
DB00575ClonidineCytochrome P450 1A1enzyme
DB00575ClonidineCytochrome P450 3A5enzyme
DB00575ClonidineAlpha-1A adrenergic receptortarget
DB00575ClonidineAlpha-1B adrenergic receptortarget
DB00575ClonidineAlpha-1D adrenergic receptortarget
DB01151DesipramineMuscarinic acetylcholine receptor M1target
DB01151DesipramineSodium-dependent noradrenaline transportertarget
DB01151DesipramineBeta-2 adrenergic receptortarget
DB01151DesipramineMuscarinic acetylcholine receptor M2target
DB01151DesipramineSodium-dependent serotonin transportertarget
DB01151DesipramineHistamine H1 receptortarget
DB01151DesipramineBeta-1 adrenergic receptortarget
DB01151DesipramineCytochrome P450 2D6enzyme
DB01151DesipramineMuscarinic acetylcholine receptor M3target
DB01151DesipramineMuscarinic acetylcholine receptor M4target
DB01151DesipramineMuscarinic acetylcholine receptor M5target
DB01151DesipramineAlpha-1 adrenergic receptorstarget
DB01151Desipramine5-hydroxytryptamine receptor 2Atarget
DB01151DesipramineAlpha-1-acid glycoprotein 1carrier
DB01151DesipramineCytochrome P450 2B6enzyme
DB01151DesipramineCytochrome P450 3A4enzyme
DB01151DesipramineSolute carrier family 22 member 2transporter
DB01151DesipramineSolute carrier family 22 member 1transporter
DB01151DesipramineSolute carrier family 22 member 3transporter
DB01151DesipramineSolute carrier family 22 member 5transporter
DB01151DesipramineMultidrug resistance protein 1transporter
DB01151DesipramineSolute carrier family 22 member 4transporter
DB01151DesipramineCytochrome P450 1A2enzyme
DB01151DesipramineCytochrome P450 2A6enzyme
DB01151DesipramineCytochrome P450 2C18enzyme
DB01151DesipramineCytochrome P450 2C19enzyme
DB01151DesipramineCytochrome P450 2E1enzyme
DB01151DesipramineSphingomyelin phosphodiesterasetarget
DB01151Desipramine5-hydroxytryptamine receptor 1Atarget
DB01151Desipramine5-hydroxytryptamine receptor 2Ctarget
DB01151DesipramineD(2) dopamine receptortarget
DB01151DesipramineAlpha-2 adrenergic receptorstarget
DB00281LidocaineSodium channel protein type 5 subunit alphatarget
DB00281LidocaineSodium channel protein type 10 subunit alphatarget
DB00281LidocaineEpidermal growth factor receptortarget
DB00281LidocaineSodium channel protein type 9 subunit alphatarget
DB00281LidocaineCytochrome P450 1A2enzyme
DB00281LidocaineCytochrome P450 2D6enzyme
DB00281LidocaineCytochrome P450 3A4enzyme
DB00281LidocaineCytochrome P450 3A5enzyme
DB00281LidocaineCytochrome P450 3A7enzyme
DB00281LidocaineSolute carrier family 22 member 5transporter
DB00281LidocaineMultidrug resistance protein 1transporter
DB00281LidocaineCytochrome P450 2A6enzyme
DB00281LidocaineCytochrome P450 2B6enzyme
DB00281LidocaineCytochrome P450 2C18enzyme
DB00281LidocaineCytochrome P450 2C8enzyme
DB00281LidocaineCytochrome P450 2C9enzyme
DB00281LidocaineSodium channel protein type 4 subunit alphatarget
DB00281LidocaineAlpha-1-acid glycoprotein 1target
DB00281LidocaineAlpha-1-acid glycoprotein 2target
DB00230PregabalinExcitatory amino acid transporter 3transporter
DB00230PregabalinVoltage-dependent calcium channel subunit alpha-2/delta-1target
DB00230PregabalinLarge neutral amino acids transporter small subunit 1transporter
DrugDrug NamePhaseStatusCount
DB06774Capsaicin1 / 2Completed1
DB00742Mannitol1 / 2Completed1
DB00083Botulinum toxin type A2Completed1
DB09119Eslicarbazepine acetate2Completed1
DB04922Gabapentin enacarbil2Completed2
DB08872Gabapentin enacarbil2Completed2
DB11998Sorivudine2Unknown Status1
DB00577Valaciclovir2Unknown Status1
DB00899Remifentanil3Unknown Status1
DB00083Botulinum toxin type A4Completed1
DB01628Etoricoxib4Unknown Status1
DB09153Sodium chloride4Completed1
DB00586DiclofenacNot AvailableCompleted1
DB01093Dimethyl sulfoxideNot AvailableCompleted1